EFISHient Protein announces successful development of Tilapia cell line

EFISHient Protein, a leading Israeli food-tech company, has announced the successful completion of its tilapia cell line development. This achievement signifies a significant advancement in the field of cultivated meat technology, paving the way for sustainable cultivated fish production.

Through cutting-edge technological capabilities, EFISHient Protein has unlocked the potential to produce muscle and fat cells of tilapia, a key step toward establishing a genetic cell bank. This milestone underscores EFISHient Protein's commitment to providing alternative protein solutions and promoting sustainable practices in the global fish products industry.

"We are thrilled to lead the way in revolutionizing the global fish products industry," said Dana Levin, CEO of EFISHient Protein, expressing immense pride and excitement about this milestone. "Completing the tilapia cell line development showcases our dedication to accelerating sustainable protein solutions, ensuring future generations can enjoy nutritious and ethical fish products".

EFISHient Protein's partnership with BioMeat Foodtech and the Volcani Institute has been instrumental in combining breakthrough technology with extensive experience in the alternative protein sector. This collaboration positions EFISHient Protein as a promising player in the cultivated fish industry, poised to deliver affordable and environmentally responsible products worldwide.

As a B2B company, EFISHient Protein is actively engaging with major fish product manufacturers globally. The company's goal is to scale up production and make their technology accessible at competitive prices, contributing to global food security while preserving marine ecosystems.